Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance.
- NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_assertion description "[Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance.
- NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_assertion evidence source_evidence_literature NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance.
- NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_assertion SIO_000772 23561477 NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance.
- NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_assertion wasDerivedFrom befree-20140225 NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance.
- NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_assertion wasGeneratedBy ECO_0000203 NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance.
- befree-20140225 importedOn "2014-02-25" NP505172.RAID0y1oMtFPUbux5FdLiO6WytPR4_lkY1aCdXCNGbAGg130_provenance.